The BONSAI phase II trial recently demonstrated the activity of cabozantinib in metastatic collecting duct patients. The outcomes of patients in this setting treated with immunotherapy as second-line is unknown. The aim of the present report was to describe outcomes of patients enrolled in the BONSAI trial that received nivolumab as second-line treatment.

BONSAI-2 study: Nivolumab as therapeutic option after cabozantinib failure in metastatic collecting duct carcinoma patients / Buti, Sebastiano; Trentini, Francesca; Sepe, Pierangela; Claps, Melanie; Isella, Luca; Verzoni, Elena; Procopio, Giuseppe. - In: TUMORI. - ISSN 0300-8916. - (2022), p. 3008916221141483. [10.1177/03008916221141483]

BONSAI-2 study: Nivolumab as therapeutic option after cabozantinib failure in metastatic collecting duct carcinoma patients

Buti, Sebastiano;Trentini, Francesca;Isella, Luca;
2022-01-01

Abstract

The BONSAI phase II trial recently demonstrated the activity of cabozantinib in metastatic collecting duct patients. The outcomes of patients in this setting treated with immunotherapy as second-line is unknown. The aim of the present report was to describe outcomes of patients enrolled in the BONSAI trial that received nivolumab as second-line treatment.
2022
BONSAI-2 study: Nivolumab as therapeutic option after cabozantinib failure in metastatic collecting duct carcinoma patients / Buti, Sebastiano; Trentini, Francesca; Sepe, Pierangela; Claps, Melanie; Isella, Luca; Verzoni, Elena; Procopio, Giuseppe. - In: TUMORI. - ISSN 0300-8916. - (2022), p. 3008916221141483. [10.1177/03008916221141483]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2935331
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 2
social impact